Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Total Non-Current Liabilities data on file, last reported at $436.5 million in Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 1.76% year-over-year to $436.5 million in Q1 2026; TTM through Mar 2026 was $436.5 million, a 1.76% increase from a year earlier, with the FY2025 full-year figure at $422.5 million, down 3.53% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $436.5 million, up from $422.5 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RNAC reached as high as $451.0 million in Q3 2024 and fell as low as $32.6 million in Q3 2023.
• Historically, Total Non-Current Liabilities has averaged $276.9 million across 5 years, with a median of $407.7 million in 2025.
• Across the five-year window, Total Non-Current Liabilities plunged 58.94% in 2022 and surged 1282.77% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $52.9 million in 2022, then soared by 729.6% to $439.0 million in 2023, then fell by 0.23% to $438.0 million in 2024, then dropped by 3.53% to $422.5 million in 2025, then grew by 3.3% to $436.5 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $436.5 million in Q1 2026, $422.5 million in Q4 2025, and $407.7 million in Q3 2025.